RepRegen is a London-based medical device company that develops products to repair and restore tissue using repair and regeneration technology across two platforms. One platform targets bone and other hard tissues; the other focuses on muscle and other soft tissues. The company is commercializing its first hard-tissue product, StronBone™, a strontium-containing bioactive glass bone graft substitute with CE Marking for orthopaedic (trauma and spine) and craniomaxillofacial applications. StronBone has not been cleared by the FDA and is limited to investigational use in the U.S. RepRegen raised new capital to continue advancing its product pipeline, pursue regulatory approvals, support commercialization programs and prepare for relevant post-market clinical studies. The company intends to deploy the funds to move products through regulatory and commercial milestones.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2010